EGFR-mutation analysis, treatment and outcomes in newly diagnosed patients with non-small cell lung cancer (NSCLC): a single-institution retrospective review

被引：1
|
作者：
Enting, D. [1 ]
Januszewski, A. [1 ]
Benepal, T. [1 ]
机构：
[1] St Georges Healthcare NHS Trust, Dept Oncol, London, England
来源：
LUNG CANCER | 2012年 / 75卷
关键词：
D O I：
10.1016/S0169-5002(12)70014-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [21] Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer
    Yokota, Hayato
    Sato, Kazuhiro
    Sakamoto, Sho
    Okuda, Yuji
    Asano, Mariko
    Takeda, Masahide
    Nakayama, Katsutoshi
    Miura, Masatomo
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (04) : 652 - 659
  • [22] Patterns of Osimertinib Dose-Reduction and Impact on Outcomes in EGFR-Mutation Positive Non-Small Cell Lung Cancer
    Ramagiri, L.
    Farid, S.
    Zhao, S.
    Li, M.
    To, B.
    Amirmokhtari, N.
    Wei, L.
    Memmott, R.
    Alahmadi, A.
    He, K.
    Kaufman, J.
    Roof, L.
    Shields, P.
    Carbone, D. P.
    Otterson, G. A.
    Presley, C. J.
    Owen, D. H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S620 - S620
  • [23] Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire
    Sharma, D.
    Slevin, F.
    Clarke, K.
    Franks, K.
    Snee, M.
    Jain, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
    Carlisle, Jennifer W.
    Ramalingam, Suresh S.
    FUTURE ONCOLOGY, 2019, 15 (08) : 805 - 816
  • [25] Impact of time to treatment initiation (TTI) on survival of patients with newly diagnosed non-small cell lung cancer (NSCLC).
    Azzouqa, Abdel-Ghani
    Chen, Ruqin
    Lou, Yanyan
    Ailawadhi, Sikander
    Manochakian, Rami
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Characteristics of EGFR, ALK, or KRAS Mutant Positive Non-Small Cell Lung Cancer (NSCLC) Patients Treated in a Single Institution
    Chung, E.
    Biswas, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E678 - E678
  • [27] Cardiovascular events in eGFR-mutation non-small-cell lung cancer patients on osimertinib
    Mensah, Samuel Akaakole
    Ahmad, Syed
    Alruwaili, Waleed
    Raval, Rutu
    Gonuguntla, Karthik
    Patel, Brijesh
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024,
  • [28] The effect of depression on survival in patients with newly diagnosed advanced non-small cell lung cancer (NSCLC).
    Temel, J. S.
    Jackson, V. A.
    Billings, A.
    Prigerson, H. G.
    Fidias, P.
    Lynch, T. J., Jr.
    Pirl, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 470S - 470S
  • [29] Evaluation of EGFR mutation testing in plasma from non-small cell lung cancer (NSCLC) patients
    Gonzalez De Aledo-Castillo, J. M.
    Victoria, I.
    Arcocha, A.
    Reguart, N.
    Molina Porto, R.
    Puig-Butille, J. A.
    CLINICA CHIMICA ACTA, 2019, 493 : S570 - S570
  • [30] Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
    Ito, Masaoki
    Codony-Servat, Cartes
    Karachaliou, Niki
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 667 - +
12345